NEW YORK, January 13, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Community Health Systems, Inc. (NYSE: CYH), ArthroCare Corporation (NASDAQ: ARTC), NuPathe, Inc. (NASDAQ: PATH), Zalicus Inc. (NASDAQ: ZLCS), and Neogen Corp. (NASDAQ: NEOG). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Community Health Systems, Inc. Research Report
On January 6, 2014, Community Health Systems Inc. (Community Health) announced its preliminary financial and operating results for full-year 2013 as well as its preliminary guidance for 2014. The Company stated that for 2013, it expects net operating revenues to range from $12.98 billion to $13.00 billion and adjusted EBITDA to range from $1.83 billion to $1.85 billion. Further, the Company also provided guidance for 2014, reflecting the acquisition of HMA as if it took place on January 1, 2014. The Company stated that it anticipates net operating revenues less provision for bad debts to range from $19.7 billion to $21.2 billion, and adjusted EBITDA for 2014 is expected to be from $2.9 billion to $3.2 billion. The Company added that it anticipates reporting its complete 2013 financial results on February 18, 2014, along with an earnings call on February 19, 2014. The Full Research Report on Community Health Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ArthroCare Corporation Research Report
On January 6, 2014, ArthroCare Corp. (ArthroCare) announced that it will present at the upcoming 32nd Annual J.P. Morgan Healthcare Conference on January 14, 2014 at 3:30 p.m. PT in San Francisco, California. ArthroCare informed that David Fitzgerald, President and CEO, will deliver the business presentation at the conference. The Company added that the presentation will be webcast live and can be accessed at its website, where it will be archived for 30 days after the presentation. The Full Research Report on ArthroCare Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
NuPathe, Inc. Research Report
On January 8, 2014, NuPathe Inc.'s (NuPathe) stock went up to end the day at $4.38 compared to the previous day's closing price of $3.23, representing a 35.60% rise. The Company's stock increased 35.19% during the past three trading days, compared to the Dow Jones Industrial Average which decreased 0.04% over the same trading period. The Full Research Report on NuPathe, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Zalicus Inc. Research Report
On January 8, 2014, Zalicus Inc.'s (Zalicus) stock went up to end the day at $1.78 compared to the previous day's closing price of $1.32, resulting in a 34.85% rise. The Company's stock increased 45.90% during the past three trading days, compared to the Dow Jones Industrial Average which decreased 0.04% over the same trading period. The Full Research Report on Zalicus Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Neogen Corp. Research Report
On January 2, 2014, Neogen Corp. (Neogen) announced its acquisition of Chem-Tech Ltd (Chem-Tech), an insecticides manufacturer for animal and food industries. James Herbert, Neogen CEO and Chairman, commented, "The Chem-Tech business will significantly add to Neogen's position of being the 'one-stop shop' for meat, milk and egg producers. Chem-Tech's Turbocide® products are also becoming popular for the fogging of food storage and warehouses." Dr. Jason Lilly, Neogen's Vice President of corporate development, added, "Chem-Tech fits the Neogen model of supplementing our organic growth with growth through acquisitions. Like many of our acquisitions, we will be able to consolidate administrative, sales, and research and development with our existing groups. We expect to continue to operate the company's manufacturing facility in Iowa along with significant portions of its warehousing and distribution." According to the Company, most of Chem-Tech's customers and distributors are already Neogen's customers, with long-term relationships with both the Companies. Neogen added that the purchase price for the acquisition includes contingent payment consideration. The Full Research Report on Neogen Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner